hnRNPK regulates Wnt/β-catenin signaling pathway to inhibit ferroptosis in breast cancer

doi:10.19401/j.cnki.1007-3639.2024.10.003

Abstract

Abstract:

Background and purpose: Heterogeneous nuclear ribonucleoprotein K (hnRNPK) is an RNA special binding protein that participates in regulating the expression of related genes and protein translation. It has been linked to the malignant occurrence and development of various tumors, but its role in breast cancer remains unclear. The aim of this study was to investigate the effects of hnRNPK on ferroptosis in breast cancer cells and the underlying mechanisms. Methods: Based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, hnRNPK expression in breast cancer tissues and normal tissues and its relationship with clinical prognosis were analyzed by bioinformatics. We detected hnRNPK expression in breast cancer cells and tissues using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry staining diagnosis methods. MCF-7 and MDA-MB-231 breast cancer cells were transfected with siRNA, and divided into control group (control), empty body group (NC), and interference vector group (si-hnRNPK). Cell proliferation was detected by cell counting kit-8 (CCK-8) and plate clone formation assays. RNA-seq analysis was applied to explore potential targeted biological functions and signaling pathways affected by hnRNPK. Additionally, we investigated the impact of hnRNPK on ferroptosis phenotype using Western blot and commercial kits for reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and Fe²⁺, ferroptosis inhibitor (ferrostatin-1, Fer-1) was used to detect the rescue effect of hnRNPK knockdown on ferroptosis. The impact of hnRNPK on the expressions of Wnt/β-catenin pathway-related proteins were determined by Western blot. Results: The bioinformatics analyses indicated hnRNPK was upregulated in breast cancer tissues (P<0.01), and the overall survival of patients in the high expression group was poorer compared with those in the low expression group (P<0.05). hnRNPK was highly expressed in breast cancer tissues and cells, and knocking down hnRNPK weakened the proliferation ability of breast cancer cells (P<0.05). The RNA-seq analysis showed that hnRNPK was significantly enriched in ferroptosis, apoptosis, and the Wnt/β-catenin signaling pathway. Knocking down hnRNPK promoted ferroptosis in breast cancer cells by inducing lipid ROS and MDA, as well as Fe²⁺ accumulation (P<0.05). Interestingly, the ferroptosis inhibitor ferrostatin-1 (Fer-1) reversed the promotive effect of hnRNPK knockdown on ferroptosis (P<0.05). Downregulation of hnRNPK led to a decrease in the expressions of β-catenin and c-Myc in the Wnt/β-catenin signaling pathway, while expressions of CK1α, APC and the GSK-3β complex were elevated (P<0.05). Conclusion: hnRNPK is highly expressed in breast cancer, and knocking down hnRNPK promotes ferroptosis in breast cancer cells by inhibiting the Wnt/β-catenin signaling pathway, thereby suppressing the malignant progression of breast cancer.

Key words: hnRNPK, Breast cancer, Ferroptosis, Wnt/β-catenin pathway

CLC Number:

R735.3

MA Xiaolan, WANG Juan, SHI Bin, WANG Nan, TIAN Zhicui, CAO Jia. hnRNPK regulates Wnt/β-catenin signaling pathway to inhibit ferroptosis in breast cancer[J]. China Oncology, 2024, 34(10): 931-943.

Figures/Tables 7

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

Fig. 7

References 23

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	WANG Z L, LI S Q, XU F, et al. ncRNAs-mediated high expression of TIMM8A correlates with poor prognosis and act as an oncogene in breast cancer[J]. Cancer Cell Int, 2022, 22(1): 177.
[3]	GADALETA E, THORN G J, ROSS-ADAMS H, et al. Field cancerization in breast cancer[J]. J Pathol, 2022, 257(4): 561-574.
[4]	SUI S Y, XU S P, PANG D. Emerging role of ferroptosis in breast cancer: new dawn for overcoming tumor progression[J]. Pharmacol Ther, 2022, 232: 107992.
[5]	LEI G, ZHUANG L, GAN B Y. Targeting ferroptosis as a vulnerability in cancer[J]. Nat Rev Cancer, 2022, 22(7): 381-396. doi: 10.1038/s41568-022-00459-0 pmid: 35338310
[6]	WANG Z Y, QIU H, HE J B, et al. The emerging roles of hnRNPK[J]. J Cell Physiol, 2020, 235(3): 1995-2008. doi: 10.1002/jcp.29186 pmid: 31538344
[7]	ZHOU W W, JIE Q L, PAN T, et al. Single-cell RNA binding protein regulatory network analyses reveal oncogenic HNRNPK-MYC signalling pathway in cancer[J]. Commun Biol, 2023, 6(1): 82.
[8]	LEE W J, SHIN C H, JI H, et al. hnRNPK-regulated LINC00263 promotes malignant phenotypes through miR-147a/CAPN2[J]. Cell Death Dis, 2021, 12(4): 290.
[9]	MUCHA B, QIE S, BAJPAI S, et al. Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translation[J]. Nat Commun, 2022, 13(1): 6614.
[10]	LI Y X, YANG Y, MA Q, et al. HNRNPK/CLCN3 axis facilitates the progression of LUAD through CAF-tumor interaction[J]. Int J Biol Sci, 2022, 18(16): 6084-6101. doi: 10.7150/ijbs.76083 pmid: 36439880
[11]	IWABUCHI E, MIKI Y, SUZUKI T, et al. Heterogeneous nuclear ribonucleoprotein K is involved in the estrogen-signaling pathway in breast cancer[J]. Int J Mol Sci, 2021, 22(5): 2581.
[12]	GALLARDO M, LEE H J, ZHANG X R, et al. hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies[J]. Cancer Cell, 2015, 28(4): 486-499. doi: S1535-6108(15)00305-0 pmid: 26412324
[13]	XU Y J, WU W, HAN Q, et al. Post-translational modification control of RNA-binding protein hnRNPK function[J]. Open Biol, 2019, 9(3): 180239.
[14]	XI Z H, HUANG H H, HU J, et al. LINC00571 drives tricarboxylic acid cycle metabolism in triple-negative breast cancer through HNRNPK/ILF2/IDH2 axis[J]. J Exp Clin Cancer Res, 2024, 43(1): 22.
[15]	ZHOU X M, ZOU L B, LIAO H Y, et al. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer[J]. Acta Pharm Sin B, 2022, 12(2): 692-707.
[16]	LV Y, TANG W T, ZHANG Z Y, et al. Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer[J]. Oncogene, 2022, 41(23): 3210-3221. doi: 10.1038/s41388-022-02284-z pmid: 35505093
[17]	ZHANG C, LIU X Y, JIN S D, et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance[J]. Mol Cancer, 2022, 21(1): 47.
[18]	CHEN X, KANG R, KROEMER G, et al. Broadening horizons: the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5): 280-296. doi: 10.1038/s41571-020-00462-0 pmid: 33514910
[19]	ZHU L Z, TIAN Q, GAO H, et al. PROX1 promotes breast cancer invasion and metastasis through WNT/β-catenin pathway via interacting with hnRNPK[J]. Int J Biol Sci, 2022, 18(5): 2032-2046. doi: 10.7150/ijbs.68960 pmid: 35342346
[20]	LIU H F, CHEN X H, YANG X J, et al. Involvement of the Wnt/β-catenin signaling pathway in the heterogenous nuclear ribonucleoprotein K-driven inhibition of proliferation and migration in head and neck squamous cell carcinoma[J]. Oncol Lett, 2020, 20(6): 394.
[21]	YU F Y, YU C H, LI F F, et al. Wnt/β-catenin signaling in cancers and targeted therapies[J]. Signal Transduct Target Ther, 2021, 6(1): 307.
[22]	LIU J Q, XIAO Q, XIAO J N, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities[J]. Signal Transduct Target Ther, 2022, 7(1): 3.
[23]	XU X F, ZHANG M F, XU F Y, et al. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities[J]. Mol Cancer, 2020, 19(1): 165.